MXPA04001951A - Coniosulfuros y sus derivados, procesos para prepararlos, y su uso como farmaceuticos. - Google Patents

Coniosulfuros y sus derivados, procesos para prepararlos, y su uso como farmaceuticos.

Info

Publication number
MXPA04001951A
MXPA04001951A MXPA04001951A MXPA04001951A MXPA04001951A MX PA04001951 A MXPA04001951 A MX PA04001951A MX PA04001951 A MXPA04001951 A MX PA04001951A MX PA04001951 A MXPA04001951 A MX PA04001951A MX PA04001951 A MXPA04001951 A MX PA04001951A
Authority
MX
Mexico
Prior art keywords
medicaments
derivatives
formula
relates
coniosulphides
Prior art date
Application number
MXPA04001951A
Other languages
English (en)
Inventor
Vertesy Laszlo
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MXPA04001951A publication Critical patent/MXPA04001951A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P11/00—Preparation of sulfur-containing organic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invencion SR relacional con compuestos de la formula (I), que se forman del microorganismo Coniochaeta ellipsoldea Udagawa, DSM 13856, o de una de sus mutaciones y/o variantes durante la fermentacion y que opcionalmente se convierten quimicamente en derivados. La invencion tambien se relaciona con un metodo para producir compuestos de la formula (I) y con el uso de los mismos como medicamentos. Ademas, la invencion se relaciona con el uso de un compuesto de la formula (VI) para producir un medicamento para el tratamiento y profilaxis de neuropatias degenerativs o enfermedad de Alzheimer. (ver formula).
MXPA04001951A 2001-09-22 2002-09-06 Coniosulfuros y sus derivados, procesos para prepararlos, y su uso como farmaceuticos. MXPA04001951A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10146737A DE10146737A1 (de) 2001-09-22 2001-09-22 Coniosulfide und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
PCT/EP2002/009977 WO2003029495A2 (de) 2001-09-22 2002-09-06 Coniosulfide und deren derivate, verfahren zur ihrer herstellung und verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
MXPA04001951A true MXPA04001951A (es) 2004-06-07

Family

ID=7699903

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001951A MXPA04001951A (es) 2001-09-22 2002-09-06 Coniosulfuros y sus derivados, procesos para prepararlos, y su uso como farmaceuticos.

Country Status (12)

Country Link
EP (2) EP1474440B1 (es)
JP (2) JP4287744B2 (es)
AR (1) AR036554A1 (es)
AT (2) ATE430131T1 (es)
AU (1) AU2002339519B2 (es)
CA (1) CA2461033C (es)
DE (3) DE10146737A1 (es)
ES (2) ES2314107T3 (es)
IL (2) IL160938A0 (es)
MX (1) MXPA04001951A (es)
PE (1) PE20030466A1 (es)
WO (1) WO2003029495A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5611967B2 (ja) * 2008-11-11 2014-10-22 シグナム バイオサイエンシーズ， インコーポレイテッド イソプレニル化合物およびその方法。
JP7318948B2 (ja) * 2018-04-13 2023-08-01 国立大学法人京都大学 微生物由来化合物を用いたアルツハイマー病の予防、治療、または診断薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210393D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
FR2740454B1 (fr) * 1995-10-26 1997-11-21 Rhone Poulenc Rorer Sa Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes
WO1998021327A1 (fr) * 1996-11-08 1998-05-22 Rhone-Poulenc Rorer S.A. Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes
IL151147A0 (en) * 2000-02-10 2003-04-10 Aventis Pharma Sa Partners of ptb1 domain of fe65, preparation and uses
DE10060810A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Coniosetin und Derivate davon, Verfahren zur Herstellung und Verwendung derselben

Also Published As

Publication number Publication date
IL160938A0 (en) 2004-08-31
ES2326563T3 (es) 2009-10-14
JP2005504131A (ja) 2005-02-10
AR036554A1 (es) 2004-09-15
WO2003029495A2 (de) 2003-04-10
ES2314107T3 (es) 2009-03-16
DE50212774D1 (de) 2008-10-23
DE10146737A1 (de) 2003-04-10
ATE430131T1 (de) 2009-05-15
JP2009149662A (ja) 2009-07-09
PE20030466A1 (es) 2003-07-08
EP1474440B1 (de) 2008-09-10
ATE407942T1 (de) 2008-09-15
WO2003029495A3 (de) 2004-02-26
CA2461033C (en) 2011-12-06
DE50213512D1 (de) 2009-06-10
AU2002339519B2 (en) 2007-02-08
EP1474440A2 (de) 2004-11-10
JP4287744B2 (ja) 2009-07-01
EP1903033A1 (de) 2008-03-26
EP1903033B1 (de) 2009-04-29
CA2461033A1 (en) 2003-04-10
IL160938A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
IL193814A0 (en) 1 -acetyl- 3,3 dimethyl- 6- amino- 2, 3 - dihydroindole and process for producing same
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
DE60318193D1 (en) Phenethanolaminderivate
GB0225475D0 (en) Therapeutic agents
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MXPA04003245A (es) Hidroxipropilaminas.
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
WO2004022523A3 (en) 1, 3-diamino-2-hydroxypropane prodrug derivatives
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
WO2003053330A3 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
EP1389616A4 (en) NEW BENZYL PIPERIDINE COMPOUND
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
MY136269A (en) Novel diphenylazetidinone, process for its preparation, medicaments comprising this compound and their use
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
PT1745010E (pt) Derivados de ciclo-hexil-1,4-diamina substituídos
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration